✦ LIBER ✦

Pioglitazone and Nonalcoholic Steatohepatitis

✍ Scribed by Guenther Boden

Publisher: Current Science Inc.
Year: 2007
Tongue: English
Weight: 90 KB
Volume: 7
Category: Article
ISSN: 1534-4827
DOI: 10.1007/s11892-007-0034-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pioglitazone for patients with type 2 di

Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis

✍ Janet King; Kris V. Kowdley 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Background: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates

A pilot study of pioglitazone treatment

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

✍ Kittichai Promrat; Glen Lutchman; Gabriel I. Uwaifo; Renee J. Freedman; Alejandr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance p

The effects of discontinuing pioglitazon

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

✍ Glen Lutchman; Apurva Modi; David E. Kleiner; Kittichai Promrat; Theo Heller; Ma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Nonalcoholic steatohepatitis

✍ Brian P. Mulhall; Zobair M. Younossi 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 341 KB

Nonalcoholic steatohepatitis in children

✍ Eve A. Roberts 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 914 KB

Insulin sensitizers in nonalcoholic stea

Insulin sensitizers in nonalcoholic steatohepatitis

✍ Stephen A. Harrison; Steven Schenker; Kenneth Cusi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB 👁 1 views

We read with great interest the article by Stepanova et al. 1 In this report from the United States with 10,582 eligible individuals (1.52% of whom were positive for hepatitis C virus [HCV] antibody [anti-HCV]), the rate of insurance coverage was significantly lower in patients with HCV infection (6